JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison
Cancer Medicine · 2025
DOI: 10.1002/cam4.71340 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hairong Xu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Neoplasms, Denosumab, Giant Cell Tumor of Bone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai JMT-Bio Technology Co., Ltd..
Abstract (Originalsprache)
Background
Giant cell tumors of bone (GCTB) are RANK/RANK‐ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients. A single‐arm, phase II study demonstrated the promising efficacy of JMT103 in unresectable or surgically challenging GCTB. Patient‐level outcomes from the single‐arm trial were compared with real‐world data from denosumab or non‐denosumab treated patients to estimate comparative efficacy in unresectable or surgically challenging GCTB.
Methods
The real‐world data were retrospectively collected from three hospitals between January 2013 and December 2023. The eligibility criteria of the two cohorts were based on the JMT103 single‐arm study. Propensity score matching was used to balance the baseline characteristics of patients in the JMT103 and the real‐world cohorts. The primary endpoint was histopathological or 12 week radiological objective tumor response rate (OTR). Secondary endpoints included tumor response rate throughout the study, objective response rate, disease control rate, and safety profiles.
Results
166 and 135 patients were finally included in the non‐denosumab and denosumab cohorts, respectively. After 1:1 nearest neighbor matching, the OTR of the JMT103 cohort was significantly higher than that of the non‐denosumab cohort (94.2% vs. 4.8%), and was comparable with that of the denosumab cohort (92.0% vs. 67.0%). The same results were observed in tumor response rate throughout the study (JMT103 vs. non‐denosumab: 94.2% vs. 4.8%, JMT103 vs. denosumab: 94.3% vs. 86.4%), objective response rate (83.5% vs. 11.1%, 87.4% vs. 80.0%), and disease control rate (100% vs. 70.4%, 100.0% vs. 98.8%).
Conclusion
JMT103 has manageable safety profiles with better effectiveness than non‐denosumab and a trend toward greater effectiveness than denosumab in patients with unresectable or surgically challenging GCTB. Trial Registration NCT05402865, NCT04255576
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
- Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
- Department of Pathology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pathology, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Hairong Xu, Weifeng Liu, Xiaohui Niu
Förderung
- Shanghai JMT-Bio Technology Co., Ltd.
Zitieren
APA
Xu, H., Zhou, Y., Wei, F., Ding, Y., Shan, H., Yang, Y., Liu, W., Jin, T., Luo, Y., Tang, F., Lu, M., He, X., Zhang, W., Yang, S., Zhang, L., Wang, J., Li, H., Tu, C., & Niu, X. (2025). JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison. Cancer Medicine. https://doi.org/10.1002/cam4.71340
Vancouver
Xu H, Zhou Y, Wei F, Ding Y, Shan H, Yang Y, et al. JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison. Cancer Medicine. 2025. doi:10.1002/cam4.71340
BibTeX
@article{Xu2025,
author = {Xu, Hairong and Zhou, Yong and Wei, Feng and Ding, Yi and Shan, Huachao and Yang, Yongkun and Liu, Weifeng and Jin, Tao and Luo, Yi and Tang, Fan and Lu, Minxun and He, Xin and Zhang, Wenli and Yang, Shaomin and Zhang, Lihua and Wang, Juan and Li, Hong and Tu, Chongqi and Niu, Xiaohui},
title = {JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71340}
}
EUVIMED